受者年龄对异基因造血干细胞移植预后的影响:CBMTRG分析
老年受者(≥50岁)3年OS率显著低于年轻受者(≤35岁),不良结局主要体现为NRM风险升高而非复发增加。
要点
- ≥50岁受者3年OS率75.5%±2.5%,低于≤35岁受者的83.1%±2.2%(HR=1.59,P=0.007)。
- 老年受者3年NRM呈升高趋势,多因素校正后未达传统统计学显著性但效应量稳定。
- 两组CIR及Ⅱ~Ⅳ度aGVHD、cGVHD累积发生率差异无统计学意义。
核心结论
- 倾向性评分匹配后,受者高龄仍与较差OS独立相关,不良结局主要表现为NRM风险升高而非复发风险增加。
研究设计与样本
- 分为年轻受者组(≤35岁)与老年受者组(≥50岁),比较OS、NRM、CIR及aGVHD/cGVHD发生率。
主要发现
- 中位随访33.4个月(95%CI:31.2~36.1个月)。
- 老年受者组3年OS率显著低于年轻受者组[(75.5±2.5)%对(83.1±2.2)%,HR=1.59,P=0.007]。
- 3年NRM老年组为(13.3±1.9)%、年轻组为(8.5±1.6)%,单因素SHR=1.61,P=0.044;多因素校正后aSHR=1.59,95%CI:0.99~2.54,P=0.053。
- 两组CIR、Ⅱ~Ⅳ度aGVHD及cGVHD累积发生率差异均无统计学意义。
- 感染是两组最主要的非复发死亡原因,老年受者组因器官功能障碍及出血死亡的比例有升高趋势。
临床怎么用
- 评估allo-HSCT候选者时,应将受者年龄≥50岁视为OS较差及NRM风险升高的独立相关因素。
- 对老年受者移植后管理应重点关注非复发死亡,尤其是感染及器官功能障碍、出血等死因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate whether recipient age independently affects outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT), including the predominant patterns of treatment failure, after adjustment for confounding factors. Methods: This retrospective, multicenter cohort study included 1 619 patients who underwent a single allo-HSCT at five transplant centers from January 1 2018, to December 31 2023. Patients were categorized into younger (≤35 years) or older recipient groups (≥50 years). After propensity score matching to balance 11 covariates, the analysis included 694 patients (347 in each group). Overall survival (OS), non-relapse mortality (NRM), cumulative incidence of relapse (CIR), and cumulative incidence of acute and chronic graft-versus-host disease (aGVHD and cGVHD) were compared between the groups. Results: The median follow-up was 33.4 months (95% CI: 31.2 - 36.1 months). The 3-year OS rate was significantly lower in older than in younger recipients (75.5% ± 2.5% vs 83.1% ± 2.2%, HR=1.59, P=0.007). The 3-year NRM was higher in older recipients [13.3% ± 1.9% vs 8.5% ± 1.6%, univariable subdistribution HR (SHR) =1.61, P=0.044]. This association did not reach conventional statistical significance after multivariable adjustment (adjusted SHR=1.59, 95% CI: 0.99 - 2.54, P=0.053) ; however, the stable effect estimate indicated clinical relevance. No statistically significant between-group differences were observed in CIR or in the cumulative incidences of grade Ⅱ-Ⅳ aGVHD and cGVHD. Infection was the leading cause of NRM in both groups, whereas the proportions of deaths attributable to organ dysfunction and bleeding were higher among older recipients. Conclusion: After propensity score matching, older recipient age remained independently associated with poorer OS. This unfavorable outcome was primarily characterized by an increased risk of NRM, rather than that of relapse. 目的: 探讨均衡混杂因素后,受者年龄是否独立影响异基因造血干细胞移植(allo-HSCT)预后及其主导的失败模式。 方法: 本研究为一项回顾性、多中心队列研究。收集5个移植中心2018年1月1日至2023年12月31日的单次allo-HSCT患者1 619例,分为年轻受者组(≤35岁)与老年受者组(≥50岁)。采用倾向性评分匹配均衡11项协变量后,694例(每组347例)纳入分析。比较两组总生存(OS)率、非复发死亡率(NRM)、累积复发率(CIR)及急慢性移植物抗宿主病(aGVHD/cGVHD)发生率。 结果: 中位随访33.4(95% CI:31.2~36.1)个月。老年受者组3年OS率显著低于年轻受者组[(75.5±2.5)%对(83.1±2.2)%,HR=1.59,P=0.007];3年NRM风险呈升高趋势[(13.3±1.9)%对(8.5±1.6)%,单因素SHR=1.61,P=0.044],但在多因素校正后未达传统统计学显著性(aSHR=1.59,95% CI:0.99~2.54,P=0.053),效应量稳定提示临床意义。两组CIR、Ⅱ~Ⅳ度aGVHD及cGVHD累积发生率差异均无统计学意义。其中,感染是两组最主要的非复发死亡原因,老年受者组因器官功能障碍及出血死亡的比例有升高趋势。 结论: 在倾向性评分匹配后,受者高龄仍与较差OS独立相关;其不良结局主要表现为NRM风险升高,而不表现为复发风险增加。.
引用
- Liang XL, Liu J, Xuan L, et al. [Impact of recipient age on outcomes of allogeneic hematopoietic stem cell transplantation: an analysis from the Chinese Bone Marrow Transplant Registry Group (CBMTRG)]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42706169. doi:10.3760/cma.j.cn121090-20260324-00150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。